Evidence map›Paper›PMID 40711711›Full record

ArticlePulmonary therapy2025

Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection.

Tejaswini Kulkarni, David A Zisman, Oksana A Shlobin, David G Kiely, Maral DerSarkissian, Eric Shen, Kevin M Maher, Meredith Broderick, Mary Beth Scholand

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05776225 (Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05776225 completednot on this map

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

TypeobservationalSponsorUnited TherapeuticsRan2023 to 2026Enrolled314ConditionsInterstitial Lung Disease, Pulmonary HypertensionArmsRight heart catheterization (RHC)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tejaswini KulkarniUniversity of Alabama at Birmingham, 1720 University Blvd, Birmingham, AL, 35294, USA.
David A ZismanCleveland Clinic, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Oksana A ShlobinInova Fairfax Hospital, 3300 Gallows Rd, Falls Church, VA, 22042, USA.
David G KielySheffield Pulmonary Vascular Disease Unit, NIHR Biomedical Research Centre, Sheffield and Clinical Medicine, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.
Maral DerSarkissianAnalysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA, 90071, USA.
Eric ShenUnited Therapeutics Corporation, 55 TW Alexander Dr, Durham, NC, 27709, USA.
Kevin M MaherUnited Therapeutics Corporation, 55 TW Alexander Dr, Durham, NC, 27709, USA.
Meredith BroderickUnited Therapeutics Corporation, 55 TW Alexander Dr, Durham, NC, 27709, USA.
Mary Beth ScholandUniversity of Utah Health, 50 North Medical Drive, Salt Lake City, UT, 84132, USA. mary.beth.scholand@hsc.utah.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA common complication of interstitial lung disease (ILD) is pulmonary hypertension (PH), which is associated with increased morbidity and mortality and worsened quality of life. In ILD, evaluating for PH is recommended prior to lung transplantation. However, this is not standardized or routinely performed in earlier stages of ILD, and guidelines lack an evidence-based approach for PH screening in this population. Furthermore, right-heart catheterization (RHC) access can be limited in many settings. The objective of PHINDER (Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection) is to prospectively develop screening strategies for PH in patients with ILD.

methodsPHINDER is a prospective, non-interventional study that will enroll approximately 200 patients with ILD treated in a variety of settings in the United States (community centers, academic institutions, etc.). Patients must be diagnosed with ILD by high-resolution computed tomography (HRCT) and must not have a previously reported mean pulmonary arterial pressure (mPAP) > 20 mmHg. To enrich the population for PH, patients must meet additional criteria on Pulmonary Function Tests, HRCT, signs/symptoms, 6-min walk test, or echocardiography. Patients will undergo a variety of routine ILD clinical assessments. Lastly, patients receive a RHC to assess for PH, defined as mPAP > 20 mmHg with pulmonary arterial wedge pressure ≤ 15 mmHg and a pulmonary vascular resistance > 2 Wood Units. All treatment decisions are at the discretion of the provider and not influenced by study participation. PLANNED OUTCOMES: Following study completion, statistical tools will be used to derive a practical model for a screening algorithm using the variables identified in the study as most predictive of PH in patients with ILD.

conclusionsUsing a previously developed list of clinical assessments from PH and ILD experts, the PHINDER study aims to be the first prospectively enrolled study to evaluate prognostic screening strategies that can be used to develop an algorithm to predict the risk of PH in patients with ILD. TRAIL REGISTRATION: NCT05776225.

Indexed as

AlgorithmInterstitial lung diseasePulmonary hemodynamicsPulmonary hypertensionRight heart catheterizationRisk scoreScreening

Identifiers

PMID40711711
PMCPMC12373579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.